ROCKVILLE, Md., June 13, 2013 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused
on the prevention and treatment of serious infectious diseases,
announced today that it will host a Multiple Sclerosis-Estriol
Investor Day on Tuesday, June 25,
2013 from 9:00 a.m. to 11:00
a.m. at the InterContinental New York Barclay Hotel in
New York City. This event will be
accessible via a live webcast through the following internet link,
https://viavid.webcasts.com/starthere.jsp?ei=1018556.
Keynote speaker, Rhonda R.
Voskuhl, M.D., will join Synthetic Biologics' executive
management remotely for the presentations. Dr. Voskuhl is
Professor, Department of Neurology, Jack H. Skirball Chair in
Multiple Sclerosis Research and Director, Multiple Sclerosis
Program at UCLA School of Medicine, and the lead investigator of
the Phase II clinical trial evaluating the Company's oral estriol
product candidate, Trimesta™, for the treatment of
relapsing-remitting multiple sclerosis (MS). An overview of MS and
the current market, as well as the history of estriol and its role
in the treatment of MS will be discussed.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of biologics for the prevention
and treatment of serious infectious diseases. The Company is
developing an oral enzyme for the prevention of C.
difficile infections, and a series of monoclonal antibody
therapies for the treatment of Pertussis and
Acinetobacter infections. In addition, the Company is
developing a drug candidate for the treatment of
relapsing-remitting multiple sclerosis and cognitive dysfunction in
multiple sclerosis. For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
To download Synthetic Biologics' investor relations mobile
device app, which allows users access to the Company's SEC
documents, press releases and events, please click on the following
links to download the IRapp on your iPhone and iPad or your Android
mobile device.
SOURCE Synthetic Biologics, Inc.